Department of Cardiovascular Surgery, Union Hospital, Fujian Medical University, Fuzhou, People's Republic of China.
J Thorac Cardiovasc Surg. 2011 Mar;141(3):631-6. doi: 10.1016/j.jtcvs.2010.07.077. Epub 2011 Jan 13.
Our objective was to evaluate the safety and feasibility of intraoperative device closure of atrial septal defects with inferior vena cava rim deficiency.
From January 2005 to December 2008, we enrolled 65 patients who had a secundum atrial septal defect with inferior vena cava rim deficiency closure in our institution. Patients were divided into 2 groups: 35 patients in group I underwent intraoperative device closure with a right lateral minithoracotomy and 30 in group II underwent open cardiac repair with a right lateral thoracotomy and cardiopulmonary bypass. Intraoperative device closure involved a minimal intercostal incision that was performed after full evaluation of the atrial septal defect by transthoracic echocardiography and the insertion of the device through the delivery sheath to occlude the atrial septal defect.
The procedure was successful in all patients. In group I, the diameter of the atrial septal defect ranged from 30 to 44 mm (mean, 35.3 ± 3.9 mm), and the size of the implanted occluder ranged from 34 to 48 mm (mean, 40 ± 2.1 mm). The total occlusion rate was 82.9% immediately after the operation, 97.1% at 3 months, and 100% at 12 and 24 months of follow-up. In group II, all patients had successful closure. A follow-up period of 12 to 24 months was obtained in both groups. During the follow-up, there was no recurrence, thrombosis, or device failure. In our comparative studies, group II had significantly longer operative time, intensive care unit stay, and hospital stay than group I (P < .001). The cost of group I was less than that of group II (20,450.9 ± 840.8 RMB vs 25,884.9 ± 701.8; P < .001).
Intraoperative device closure of atrial septal defects with inferior vena cava rim deficiency is a safe and feasible technique. It has the advantages of cost savings, cosmetic results, and less trauma than surgical closure. Early and midterm results are encouraging.
本研究旨在评估术中应用器械闭合下腔静脉瓣环发育不良型房间隔缺损的安全性和可行性。
2005 年 1 月至 2008 年 12 月,我们共收治了 65 例下腔静脉瓣环发育不良型房间隔缺损患者,将其分为两组:其中 35 例患者行右外侧小切口微创房间隔缺损封堵术(I 组),30 例患者行右外侧开胸体外循环下心房间隔缺损修补术(II 组)。微创组通过小切口完成经胸超声心动图对房间隔缺损的全面评估,并通过输送鞘管将封堵器插入以闭合房间隔缺损;开胸组通过右外侧开胸完成体外循环下心房间隔缺损修补。
所有患者均手术成功。I 组患者的房间隔缺损直径为 3044 mm(平均 35.3 ± 3.9 mm),植入的封堵器直径为 3448 mm(平均 40 ± 2.1 mm)。术后即刻封堵成功率为 82.9%,术后 3 个月为 97.1%,术后 12 个月及 24 个月随访时均为 100%。II 组患者均成功完成房间隔缺损修补。两组患者均获得 12~24 个月的随访。随访期间,两组均无复发、血栓形成或器械故障。在我们的对比研究中,II 组的手术时间、重症监护病房停留时间和住院时间均明显长于 I 组(P <.001)。I 组的费用也明显少于 II 组(20450.9 ± 840.8 RMB 比 25884.9 ± 701.8 RMB,P <.001)。
术中应用器械闭合下腔静脉瓣环发育不良型房间隔缺损是一种安全、可行的技术。与外科修补相比,该技术具有节省成本、美容效果好、创伤小的优点。早期和中期结果令人鼓舞。